Lactoferrin vs. Ferrous Sulfate Through a Metallomics Lens

What the evidence examines

Ferrous sulfate is the default oral treatment for iron-deficiency anemia (IDA), but its high dose of poorly absorbed ferrous iron (Fe2+) frequently causes nausea, abdominal pain, and constipation, and much of the dose is never absorbed. Lactoferrin is an iron-binding glycoprotein found in milk, saliva, and neutrophil granules that carries iron in a tightly chelated ferric (Fe3+) form and doubles as a host-defense and immunomodulatory molecule. The comparison asks a metallomics question: does the chemical form and delivery of the same metal change both how well it is used and what it does to the gut?

The strongest synthesis is a 2022 meta-analysis in Nutrients (Zhao et al.) pooling 11 clinical trials and 1,262 participants (680 assigned to lactoferrin, 582 to ferrous sulfate). It is complemented by head-to-head randomized trials in specific populations, including a double-blind trial of 100 pregnant women with IDA (Nappi et al., Acta Obstetricia et Gynecologica Scandinavica, 2009) and a randomized trial in 80 children with inflammatory bowel disease (IBD)–associated IDA (El Amrousy et al., Pediatric Research, 2022). Together they cover hematologic recovery, inflammatory signaling, and tolerability.

Key findings: iron repletion and tolerability

In the 2022 meta-analysis, lactoferrin produced significantly better iron indices than ferrous sulfate: hemoglobin was higher by a weighted mean difference of about 11.8 g/L, serum iron by about 41.4 ug/dL, and ferritin by about 13.6 ng/mL (all favoring lactoferrin). Notably, fractional (percentage) iron absorption was slightly lower with lactoferrin, yet net iron status improved more, consistent with lactoferrin working through the body's regulatory pathways rather than by brute-force luminal delivery.

Tolerability differences are large and clinically meaningful. In the pregnancy trial, both agents raised hemoglobin, serum ferritin, and iron similarly, but abdominal pain and constipation scores were significantly higher with ferrous sulfate. In the pediatric IBD trial, side effects occurred in roughly 2.5% of the lactoferrin group versus about 46% of the ferrous sulfate group, while the lactoferrin group reached significantly higher hemoglobin. Better tolerability translates into better adherence, which is a major reason ferrous sulfate courses fail in practice.

The mechanism: the IL-6–hepcidin–ferroportin axis

Iron absorption is governed by hepcidin, a liver hormone that binds and degrades ferroportin, the only known cellular iron exporter on enterocytes and macrophages. When ferroportin is destroyed, dietary iron is trapped in gut cells and recycled iron is locked in macrophages, producing the functional iron restriction seen in anemia of inflammation. The pro-inflammatory cytokine interleukin-6 (IL-6) is a primary driver of hepcidin transcription via JAK/STAT3 signaling.

Lactoferrin appears to act on this regulatory node. The 2022 meta-analysis found IL-6 was lower by a weighted mean difference of roughly 45.6 pg/mL in lactoferrin-treated patients, and the pediatric IBD trial reported that lactoferrin significantly reduced both IL-6 and hepcidin-25, whereas ferrous sulfate did not. By lowering IL-6, lactoferrin relieves hepcidin-mediated suppression of ferroportin, restoring iron export from enterocytes into the circulation. This is a fundamentally different logic from ferrous sulfate, which floods the gut lumen with iron but does nothing to lift the inflammatory brake on absorption, and may even add oxidative stress that reinforces it.

Gentler on the microbiome: unabsorbed luminal iron and dysbiosis

Only a fraction of a ferrous sulfate dose is absorbed; the remainder passes into the colon as reactive, bioavailable iron. Separate microbiome research shows this unabsorbed luminal iron is not neutral. Controlled studies and models report that oral ferrous iron can favor blooms of Enterobacteriaceae (including potentially pathogenic Escherichia and Shigella), increase enteropathogenic E. coli virulence-gene expression, generate reactive oxygen species, and shift short-chain fatty acid profiles, and that oral iron can exacerbate colitis in susceptible hosts (e.g., Zhao et al., 2018, PLOS One; Tang et al., Microbiology Spectrum, 2023).

Lactoferrin changes this luminal exposure. It withholds iron from pathogens through nutritional immunity, keeps iron chelated rather than free, and has intrinsic antimicrobial and prebiotic-like effects that favor commensals such as bifidobacteria. Because it corrects iron status with a smaller, better-regulated iron load reaching the colon, it repletes iron with less of the pro-inflammatory dysbiosis linked to conventional salts. A caveat worth stating plainly: the head-to-head lactoferrin-versus-ferrous-sulfate trials measured gastrointestinal tolerability rather than sequencing the microbiome directly, so the microbiome advantage is inferred from tolerability data plus the broader oral-iron microbiome literature rather than from a direct comparative sequencing study.

How it fits the metal–microbiome–disease axis

Iron is the metal at the center of this story, and its handling illustrates the metal–microbiome–disease axis directly. An excess of poorly absorbed, redox-active iron in the gut can reshape the microbiome toward pro-inflammatory, pathogen-favoring communities, and that dysbiosis is mechanistically tied to intestinal inflammation and IBD flares. In other words, the way a metal is delivered can itself become an upstream driver of disease through the microbiome.

Lactoferrin is a useful counterexample and therapeutic lever: it repairs a genuine metal deficiency without paying the dysbiotic and inflammatory cost, in part because it engages the host's own metalloregulatory machinery (hepcidin, ferroportin) instead of overwhelming the lumen. Framed this way, the choice between lactoferrin and ferrous sulfate is not only about hematology but about metallostasis: matching the chemical form of a supplemented metal to the biology of both the host and the microbiome so that correcting a deficiency does not seed downstream disease.